Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics : A cross-sectional study using baseline data

Kusumi, Ichiro; Ito, Koki; Honda, Minoru; Hayashishita, Tadayuki; Uemura, Keiichi; Hashimoto, Naoki; Murasaki, Mitsukuni; Atsumi, Yoshihito; Kadowaki, Takashi; Koyama, Tsukasa

Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics : A cross-sectional study using baseline data

Kusumi, Ichiro; Ito, Koki; Honda, Minoru et al.

Psychiatry and Clinical Neurosciences, 2011, 65(4), 349-355

Permalink : https://hdl.handle.net/2115/49341

このアイテムのアクセス数:1,307件（2026-08-07 21:29 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
PCN65-4_349-355	pdf	140 KB	1,420

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/49341
タイトル	Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics : A cross-sectional study using baseline data
著者	Kusumi, Ichiro ; Ito, Koki ; Honda, Minoru ; Hayashishita, Tadayuki ; Uemura, Keiichi ; Hashimoto, Naoki ; Murasaki, Mitsukuni ; Atsumi, Yoshihito ; Kadowaki, Takashi ; Koyama, Tsukasa
e-Rad_Researcher 30250426 著者名 Kusumi, Ichiro
著者名 Ito, Koki
著者名 Honda, Minoru
著者名 Hayashishita, Tadayuki
著者名 Uemura, Keiichi
著者名 Hashimoto, Naoki
著者名 Murasaki, Mitsukuni
著者名 Atsumi, Yoshihito
著者名 Kadowaki, Takashi
e-Rad_Researcher 10113557 著者名 Koyama, Tsukasa
言語	英語
キーワード	diabetes mellitus
	glucose monitoring guidance
	metabolic abnormality
	schizophrenia
	second-generation antipsychotic
発行日	2011-06
出版者	Blackwell Publishing
収録物名	Psychiatry and Clinical Neurosciences
巻(号)	65(4)
ページ	349-355
抄録	Aim: The Japanese blood glucose monitoring guidance for patients receiving second-generation antipsychotics has been newly developed. We aimed to report a cross-sectional study using a baseline data of the Japanese monitoring guidance to find undiagnosed hyperglycemia systematically as a routine clinical practice and to quantify the frequency of glucose abnormalities in schizophrenia patients treated with second-generation antipsychotics. Methods: Data for 537 patients with schizophrenia who had not been diagnosed as diabetes prior to baseline screening and started the monitoring between June 2008 and January 2009, were collected from medical records in 25 hospitals. Blood glucose (fasting or casual), hemoglobin_[A1c], serum lipids, height/weight, clinical diabetic symptoms, and family history of diabetes were assessed. Patients were classified into normal, pre-diabetic or probable diabetic type based on their values of blood glucose or hemoglobin_[A1c], and various background characteristics and serum lipid values were compared among the three types. Results: Out of 537 patients, 13 (2.4%) met criteria for probable diabetic type, 51 (9.5%) for pre-diabetic type, and 473 (88.1%) for normal type. Individuals categorized as probable diabetic type had a higher body mass index and higher frequency of family history of diabetes mellitus than those within normal type. Conclusion: Glucose abnormalities were newly detected in 11.9% of schizophrenia patients treated with second-generation antipsychotics by the baseline monitoring. To assess the detective power and usefulness of the guidance, longitudinal investigations are necessary.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The definitive version is available at www.wileyonlinelibrary.com
PISSN	1323-1316
関連情報	PMID 21545674
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1111/j.1440-1819.2011.02218.x